var data={"title":"Doxazosin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Doxazosin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6072?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=doxazosin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Doxazosin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=doxazosin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Doxazosin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162904\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cardura;</li>\n      <li>Cardura XL</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162905\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Doxazosin;</li>\n      <li>Cardura-1;</li>\n      <li>Cardura-2;</li>\n      <li>Cardura-4;</li>\n      <li>Dom-Doxazosin;</li>\n      <li>Doxazosin-1;</li>\n      <li>Doxazosin-2;</li>\n      <li>Doxazosin-4;</li>\n      <li>Mylan-Doxazosin;</li>\n      <li>PMS-Doxazosin;</li>\n      <li>Teva-Doxazosin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162945\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha <sub>1</sub> Blocker;</li>\n      <li>\n        Antihypertensive</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162909\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>BPH:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Immediate release:</i> Initial: 1 mg once daily; may titrate (by doubling the daily dose [eg, to 2 mg, then 4 mg, then 8 mg])  at 1- to 2-week intervals up to 8 mg once daily based on patient response and tolerability (maximum: 8 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Reinitiation of therapy: If therapy is discontinued for several days, restart at 1 mg dose and titrate using initial dosing regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Extended release:</i> 4 mg once daily; may titrate based on response and tolerability every 3 to 4 weeks to 8 mg once daily (maximum: 8 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Reinitiation of therapy: If therapy is discontinued for several days, restart at 4 mg dose and titrate using initial dosing regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> Conversion to extended release from immediate release: Omit final evening dose of immediate release prior to starting morning dosing with extended release product; initiate extended release product using 4 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypertension:</b> Oral: <i>Immediate release:</i> Initial: 1 mg once daily; may titrate by doubling the daily dosage   up to 16 mg once daily based on blood pressure response; usual dosage range (ASH/ISH [Weber 2014]): 1 to 2 mg once daily; Maximum: 16 mg/day. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reinitiation of therapy: If therapy is discontinued for several days, restart at 1 mg dose and titrate using initial dosing regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ureteral calculi (distal) expulsion (off-label use):</b> Oral: <i>Immediate release:</i> 4 mg once daily in evening (Gurbuz 2011; Resorlu 2011). <b>Note:</b> Patients with stones &gt;10 mm were excluded from studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4473154\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=doxazosin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Doxazosin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Hypertension (off-label use):</b> Children and Adolescents 1 to 17 years: Oral: Immediate release: Initial: 1 mg once daily; maximum: 4 mg/day (NHBPEP 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162910\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. In the management of hypertension, consider lower initial doses (eg, immediate release: 0.5 mg once daily) and titrate to response (Aronow 2011) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15788950\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (however, limited data suggest renal impairment does not significantly alter pharmacokinetic parameters).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932031\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild to moderate impairment (Child-Pugh class A or B): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment (Child-Pugh class C): Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162884\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardura: 1 mg, 2 mg, 4 mg, 8 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg, 2 mg, 4 mg, 8 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardura XL: 4 mg, 8 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162869\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162887\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Swallow tablets whole; do not crush, cut, chew, or divide. Administer with morning meal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Administer daily dose either in the morning or evening.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162886\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Benign prostatic hyperplasia:</b> Treatment of signs and symptoms of benign prostatic hyperplasia (BPH). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension (immediate release only):</b> Management of hypertension (monotherapy or in combination with other antihypertensives).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]) does <b>not</b> recommend the use of doxazosin in the treatment of hypertension (JNC8 [James 2013]). According to the AHA/ACC/ASH 2015 scientific statement for the treatment of hypertension in patients with coronary artery disease (CAD), doxazosin should only be used if other drugs for the management of hypertension and heart failure do not achieve BP control at maximum tolerated doses (AHA/ACC/ASH [Rosendorff 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725320\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Pediatric hypertension; Ureteral calculi (distal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162953\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Doxazosin may be confused with doxapram, doxepin, DOXOrubicin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cardura may be confused with Cardene, Cordarone, Cordran, Coumadin, K-Dur, Ridaura</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Doxazosin is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its high risk of orthostatic hypotension. Avoid use for hypertension treatment (alternative agents have superior risk-benefit profiles) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162876\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Central nervous system: Dizziness (5% to 19%), malaise (&le;12%), fatigue (8% to &le;12%), headache (6% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema (3% to 4%), hypotension (1% to 2%), orthostatic hypotension (&lt;1% to 2%), cardiac arrhythmia (1%), facial edema (1%), flushing (1%), palpitations (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Drowsiness (1% to 5%), vertigo (2% to 4%), pain (2%), anxiety (1%), ataxia (1%), hypertonia (1%), insomnia (1%), movement disorder (1%), myasthenia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Sexual disorder (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain (2%), nausea (1% to 2%), dyspepsia (1%), xerostomia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary incontinence (1%), urinary tract infection (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (4% to 7%), muscle cramps (1%), myalgia (1%), arthralgia (&le;1%), arthritis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Visual disturbance (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Tinnitus (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Polyuria (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Respiratory tract infection (5%), rhinitis (3%), dyspnea (1% to 3%), epistaxis (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, abnormal lacrimation, abnormality in thinking, agitation, alopecia, altered sense of smell, amnesia, angina pectoris, anorexia, back pain, blurred vision, bradycardia, bronchospasm (aggravated), cerebrovascular accident, chest pain, cholestasis, cholestatic hepatitis, confusion, cough, decreased libido, depersonalization, diaphoresis, diarrhea, dysgeusia, dysuria, eczema, emotional lability, fecal incontinence, fever, flu-like symptoms, gastroenteritis, gastrointestinal obstruction, gout, gynecomastia, hematuria, hepatitis, hot flash, hypersensitivity reaction, hypoesthesia, hypokalemia, impotence, increased appetite, increased thirst, infection, intraoperative floppy iris syndrome (cataract surgery), jaundice, lack of concentration, leukopenia, lymphadenopathy, mastalgia, migraine, myocardial infarction, nephrolithiasis, nervousness, neutropenia, nocturia, orthostatic dizziness, otalgia, pallor, paranoia, paresis, paresthesia, peripheral ischemia, pharyngitis, photophobia, priapism, pruritus, purpura, rigors, sinusitis, skin rash, syncope, tachycardia, thrombocytopenia, tremor, twitching, urinary frequency, urination disorder, urticaria, vomiting, weight gain, weight loss, xeroderma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162890\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to doxazosin, other quinazolines (eg, prazosin, terazosin), or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162873\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic reactions: May occur, including skin rash, urticaria, pruritus, angioedema, and respiratory symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha<sub>1</sub>-blockers; there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. May require modifications to surgical technique.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effect: Decreases in white blood cells (WBC) and neutrophil count have been reported; WBC and neutrophils returned to normal after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension/syncope: May cause orthostatic hypotension and syncope within a few hours after dosing, but may occur later; anticipate a similar effect if therapy is interrupted for a few days, if dosage is increased, or if another antihypertensive drug, PDE-5 inhibitor, or nitrates are introduced. Use with caution in patients with symptomatic orthostatic hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Priapism has been associated with use (rarely); seek immediate medical assistance for erections lasting longer than 4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart failure, angina pectoris, or recent acute myocardial infarction (within the last 6 months). If symptoms of angina pectoris appear or worsen, discontinue use. In a scientific statement from the American Heart Association, doxazosin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with mild to moderate impairment (Child-Pugh class A and B); monitor blood pressure and for symptoms of hypotension. Not recommended in severe impairment (Child-Pugh class C) (extensively metabolized).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostate cancer: Rule out prostatic carcinoma before beginning therapy (many symptoms of BPH and prostate cancer are similar).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended release: Consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction. Use caution in patients with increased GI retention (eg, chronic constipation) as doxazosin exposure may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warning/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Extended release: Not indicated for use in women or for the treatment of hypertension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299231\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162878\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9389&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Doxazosin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers (Nonselective). Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2931842\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse events were observed in some animal reproduction studies. Doxazosin crosses the placenta (Versmissen  2016). Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for hypertension during pregnancy is needed, other agents are generally preferred (ACOG, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097533\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Doxazosin is present in breast milk. Information is available from a single case report following a maternal dose of doxazosin 4 mg every 24 hours for 2 doses. Milk samples were obtained at various intervals over 24 hours, beginning ~17 hours after the first dose. Maternal serum samples were obtained at nearly the same times, beginning ~1 hour later. The highest serum and milk concentrations of doxazosin were observed ~1 hour after the dose. Using the highest milk concentration (4.15 mcg/L), the estimated dose to the breastfeeding infant was calculated to be &lt;1% of the weight-adjusted maternal dose (Jensen, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932026\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Administer extended-release tablet with morning meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162882\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure routinely and for at least 6 hours after initial dose and with each dose increase (standing and sitting/supine); monitor patients with mild-to-moderate impairment for symptoms of hypotension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162872\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;text-align:justify;\">Hypertension: Competitively inhibits postsynaptic alpha<sub>1</sub>-adrenergic receptors which results in vasodilation of veins and arterioles and a decrease in total peripheral resistance and blood pressure; ~50% as potent on a weight by weight basis as prazosin.</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">BPH: Competitively inhibits postsynaptic alpha<sub>1</sub>-adrenergic receptors in prostatic stromal and bladder neck tissues. This reduces the sympathetic tone-induced urethral stricture causing BPH symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162889\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &gt;24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~98%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic to active metabolites; primarily via CYP3A4; secondary pathways involve CYP2D6 and 2C9</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Immediate release: ~65%; Extended release relative to immediate release: 54% to 59%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Immediate release: ~22 hours; Extended release: 15 to 19 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Immediate release: 2 to 3 hours; Extended release: 8 &plusmn;  3.7 to 9 &plusmn; 4.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~63%, primarily as metabolites [4.8% as unchanged]); urine (9%, primarily as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162893\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Cardura XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $192.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (30): $202.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cardura Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $558.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $558.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $586.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (100): $615.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Doxazosin Mesylate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $134.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $134.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $141.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (100): $148.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162894\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alfadil (SE);</li>\n      <li>Alfadil XL (PH);</li>\n      <li>Alfamedin (DE);</li>\n      <li>Cadex (IL);</li>\n      <li>Cadil (KR);</li>\n      <li>Cadlin (KR);</li>\n      <li>Cardenalin (JP);</li>\n      <li>Cardolin-2 (TH);</li>\n      <li>Cardular (DE, LB);</li>\n      <li>Cardular PP (DE);</li>\n      <li>Cardular Uro (DE);</li>\n      <li>Cardura (AE, AR, BB, BG, BH, CL, CO, CR, CY, CZ, DO, EG, GB, GR, GT, HK, HN, HU, ID, IE, IQ, IR, JO, KW, LT, LU, LY, MT, MX, MY, NI, NL, OM, PA, PK, PT, QA, RU, SA, SG, SV, SY, TH, TR, UY, VE, YE, ZA, ZM);</li>\n      <li>Cardura CR (CH);</li>\n      <li>Cardura XL (CL, CN, CO, CR, DO, EE, GT, HK, HN, LT, LU, MT, MY, NI, PA, PE, PL, RO, SI, SK, SV, TH);</li>\n      <li>Cardura-XL S.R. (KR);</li>\n      <li>Carduran (AU, NO, VN);</li>\n      <li>Carduran Neo (ES);</li>\n      <li>Carduran Retard (DK, IS);</li>\n      <li>Carduran XL (BR);</li>\n      <li>Cazosin (TH);</li>\n      <li>Dalgen (CO);</li>\n      <li>Dedralen (IT);</li>\n      <li>Diblocin (DE);</li>\n      <li>Diblocin PP (DE);</li>\n      <li>Diblocin Uro (DE);</li>\n      <li>Doka (HR);</li>\n      <li>Dophilin (TW);</li>\n      <li>Dorbantil (PY);</li>\n      <li>Dosabin (TW);</li>\n      <li>Dosan (NZ);</li>\n      <li>Dovozin (TH);</li>\n      <li>Doxaben (TW);</li>\n      <li>Doxaben XL (TW);</li>\n      <li>Doxacar (IE);</li>\n      <li>Doxacard (IN);</li>\n      <li>Doxacor (PE);</li>\n      <li>Doxagamma (DE);</li>\n      <li>Doxagen (QA);</li>\n      <li>Doxan (TW);</li>\n      <li>Doxane (IE);</li>\n      <li>Doxatan (IE, MT);</li>\n      <li>Doxazone XL SR (KR);</li>\n      <li>Doxolbran (AR);</li>\n      <li>Genzosin (TW);</li>\n      <li>Jutalar (DE);</li>\n      <li>Kamiren (HR, RO, UA);</li>\n      <li>Kamiren XL (MY, UA);</li>\n      <li>Kinxaben (TW);</li>\n      <li>Maguran (GR);</li>\n      <li>Magurol (JO, LK, MT, MY);</li>\n      <li>Mahurol (UA);</li>\n      <li>Pencor (HK, MY, SG, TH);</li>\n      <li>Progandol (ES);</li>\n      <li>Prostasin (TH);</li>\n      <li>Pzocin XL (KR);</li>\n      <li>Saxobin (TW);</li>\n      <li>Supressin (AT);</li>\n      <li>Tensidox (ID);</li>\n      <li>Tonocardin (HR);</li>\n      <li>Tonokardin (HR);</li>\n      <li>Uriduct (DE);</li>\n      <li>Xadosin (TW);</li>\n      <li>Xadosin XL (TW);</li>\n      <li>Zoxan (VN);</li>\n      <li>Zoxan LP (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&rsquo; Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2011, 123(21):2434-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/21518977/pubmed\" target=\"_blank\" id=\"21518977\">21518977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardura (doxazosin) [prescribing information]. New York, NY: Pfizer; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardura XL (doxazosin) [prescribing information]. New York, New York: Pfizer; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardura (doxazosin) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis BR, Cutler JA, Gordon DJ, et al, &ldquo;Rationale and Design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group,&rdquo; <i>Am J Hypertens</i>, 1996, 9(4 Pt 1):342-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/8722437/pubmed\" target=\"_blank\" id=\"8722437\">8722437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gurbuz MC, Polat H, Canat L, et al, &ldquo;Efficacy of Three Different Alpha 1-Adrenergic Blockers and Hyoscine N-butylbromide for Distal Ureteral Stones,&rdquo; <i>Int Braz J Urol</i>, 2011, 37(2):195-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/21557836/pubmed\" target=\"_blank\" id=\"21557836\">21557836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jensen BP, Dalrymple JM, and Begg EJ, &quot;Transfer of Doxazosin Into Breast Milk,&quot; <i>J Hum Lact</i>, 2013, 29(2):150-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/23439864/pubmed\" target=\"_blank\" id=\"23439864\">23439864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group,&rdquo; <i>JAMA</i>, 2000, 283(15):1967-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/10789664/pubmed\" target=\"_blank\" id=\"10789664\">10789664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McConnell JD, Roehrborn CG, Bautista OM, et al, &ldquo;The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group,&rdquo; <i>N Engl J Med</i>, 2003, 349(25):2387-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/14681504/pubmed\" target=\"_blank\" id=\"14681504\">14681504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&rdquo; Clinical Practice Guidelines, 2011, National Institutes of Health. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program (NHBPEP) Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo; <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15636433\"></a>Pulcrano M, Palmieri EA, Pagano L, et al. Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning paraganglioma. <i>J Endocrinol Invest.</i> 2004;27(8):774-777.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/15636433/pubmed\" target=\"_blank\" id=\"15636433\">15636433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Resorlu B, Boskurt OF, Senocak C, et al, &ldquo;Effectiveness of Doxazosin in the Management of Lower Ureteral Stones in Male and Female Patients,&rdquo; <i>Int Urol Nephrol</i>, 2011, 43(3):645-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/21072591/pubmed\" target=\"_blank\" id=\"21072591\">21072591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/25840695/pubmed\" target=\"_blank\" id=\"25840695\">25840695</a>]</span><span class=\"doi\">10.1016/j.jash.2015.03.002</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15960647\"></a>Seefelder C, Sparks JW, Chirnomas D, et al. Perioperative management of a child with severe hypertension from a catecholamine secreting neuroblastoma.<i>Paediatr Anaesth</i>. 2005;15(7):606-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/15960647/pubmed\" target=\"_blank\" id=\"15960647\">15960647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Versmissen J, Koch BC, Roofthooft DW, et al. Doxazosin treatment of phaeochromocytoma during pregnancy: placental transfer and disposition in breast milk. <i>Br J Clin Pharmacol</i>. 2016;82(2):568-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/27194370/pubmed\" target=\"_blank\" id=\"27194370\">27194370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxazosin-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9389 Version 215.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F162904\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F162905\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F162945\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F162909\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F4473154\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F162910\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15788950\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F2932031\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F162884\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F162869\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F162887\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F162886\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725320\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F162953\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F162876\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F162890\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F162873\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299231\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F162878\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2931842\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8097533\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2932026\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F162882\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F162872\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F162889\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F162893\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F162894\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9389|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=doxazosin-patient-drug-information\" class=\"drug drug_patient\">Doxazosin: Patient drug information</a></li><li><a href=\"topic.htm?path=doxazosin-pediatric-drug-information\" class=\"drug drug_pediatric\">Doxazosin: Pediatric drug information</a></li></ul></div></div>","javascript":null}